Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus

Annals of Neurology

Volumn 67, Issue 6, 2010, Pages 726-738

  Cavalcante, Paola ^a   Serafini, Barbara ^b   Rosicarelli, Barbara ^b   Maggi, Lorenzo ^a   Barberis, Massimo ^c   Antozzi, Carlo ^a   Berrih Aknin, Sonia ^d   Bernasconi, Pia ^a   Aloisi, Francesca ^b   Mantegazza, Renato ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; GLYCOPROTEIN GP 350; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN BDCA2; PROTEIN BFRF1; PROTEIN BMRF1; PROTEIN LMP1; PROTEIN LMP2A; PROTEIN P160; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MYASTHENIA GRAVIS; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYMUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIGENS, CD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HISTOCOMPATIBILITY ANTIGENS; HUMANS; LYMPHOID TISSUE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RNA, VIRAL; THYMUS GLAND; VIRAL PROTEINS; YOUNG ADULT;

EID: 77952920585     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21902     Document Type: Article

References (39)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797-804.
2. Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis sero-negative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008;1132:84-92. (Pubitemid 351841363)
3. Marx A, Wilisch A, Schultz A, et al. Pathogenesis of myasthenia gravis. Virchows Arch 1997;430:355-364.
4. Lauriola L, Ranelletti MD, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536-538. (Pubitemid 40189877)
5. Hill ME, Shiono H, Newsom-Davis J, Willcox N. The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J Neuroimmunol 2008;201-202:50-56.
6. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990;28:312-319. (Pubitemid 20292616)
7. Schluep M, Willcox N, Vincent A, et al. Acetylcholine receptor in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987;22:212-222.
8. Wakkach A, Guyon T, Bruand C, et al. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996;157:3752-3760.
9. Okumura M, Ohta M, Takeuchi Y, et al. The immunological role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer. J Thorac Cardiovasc Surg 2003;126:1922-1928.
10. Sonett JR, Jaretzki A III. Thymectomy for nonthymomatous myasthenia gravis. A critical analysis. Ann N Y Acad Sci 2008;1132:315-328.
11. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005;25:74-80.
12. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008;41:298-328.
13. Klavinskis LS, Willcox N, Oxford JS, Newsom-Davis J. Antivirus antibodies in myasthenia gravis. Neurology 1985;35:1381-1384.
14. Klavinskis LS, Willcox HN, Richmond JE, Newsom-Davis J. Attempted isolation of viruses from myasthenia gravis thymus. J Neuroimmunol 1986;11:287-299.
15. McGuire LJ, Huang DP, Teoh R, et al. Epstein-Barr virus genome in thymoma and thymic lymphoid hyperplasia. Am J Pathol 1988;131:385-390.
16. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-2912.
17. Thorley-Lawson D. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
18. Chen F, Zou J-Z, Di Renzo L, et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 1995;69:3752-3758.
19. + T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol 2000;74:6675-6679.
20. Stevens SJC, Vervoort MBHJ, van den Brule AJC, et al. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR. J Clin Microbiol 1999;37:2852-2857.
21. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol 2002;117:259-267.
22. Neuhierl B, Delecluse HJ. The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication. J Virol 2006;80:5078-5081.
23. Granato M, Farina A, Gonnella R, et al. Regulation of the expression of the Epstein-Barr virus early gene BFRF1. Virology 2006;347:109-116.
24. Babcock GJ, Hochberg D, Thorley-Lawson DA. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000;13:497-506.
25. Bhibhatbhan A, Kline G, Vincent A, Toth C. Anti-MuSK myasthenia gravis presenting with Epstein-Barr virus-associated mononucleosis and immune-mediated diabetes mellitus. Muscle Nerve 2007;36:264-266.
26. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-812.
27. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998;17:1700-1709.
28. Swanson-Mungerson M, Longnecker R. Epstein-Barr virus latent membrane protein 2A and autoimmunity. Trends Immunol 2007;28:213-218. (Pubitemid 46667241)
29. Henderson S, Rowe M, Gregory C, et al. Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-1115.
30. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003;171:5215-5224.
31. Wang H, Nicholas MW, Conway KL, et al. EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity. J Immunol 2006;177:2793-2802.
32. Shiono H, Fujii Y, Okumura M, et al. Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis. Eur J Immunol 1997;27:805-809.
33. Thangarajh M, Masterman T, Helgeland L, et al. The thymus is a source of B-cell-survival factors - APRIL and BAFF - in myasthenia gravis. J Neuroimmunol 2006;178:161-166.
34. Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001;167:1935-1944.
35. Herlands RA, Christensen RA, Sweet RA, et al. T-cell independent and Toll-like receptor dependent antigen-driven activation of autoreactive B cells. Immunity 2008;29:249-260.
36. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields virology. 5th ed. Philadelphia, PA: Lippincott-Williams & Wilkins, 2007:2655-2700.
37. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008;22:883-896.
38. Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol 1995;103:308-315.
39. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-250.